The Advisory Committee on Immunization Practices, which advises the Centers for Disease Control and Prevention, meets on June 29-30 and will consider pertussis boosters. Combined acellular pertussis vaccines for adolescents and adults are available in Canada, Australia, and Germany.
Led by Grace Lee, MD, MPH, Harvard Medical School Instructor of Ambulatory Care and Prevention at the Department of Ambulatory Care and Prevention's Center for Child Health Care Studies, the researchers compared six vaccination strategies, ranging from no vaccination after age 6 to adolescent and adult vaccination with 10-year boosters. The computer simulation model used incorporated existing data on pertussis incidence, disease outcomes, vaccine efficacy, vaccine costs, and side effects. (The Department of Ambulatory Care and Prevention is a unique research and teaching collaboration between Harvard Pilgrim Health Care and Harvard Medical School.)
The analysis concluded that one-time adolescent vaccination "would result in significant net health benefits and may be reasonably cost-effective," preventing 36 percent of projected pertussis cases at a cost of $20,000 per quality-adjusted life year saved or $1,100 per case prevented. These estimates -- less favorable than those for Haemophilius influenza B (Hib) or measles vaccination, but similar to those for pneumococcal vaccination -- were highly sensitive to assumptions about disease incidence, vaccine efficacy, side effects, and vaccine costs, the authors write.
"In the past, vaccination programs were cost-saving and life-saving," says Lee, who is also an infectious disease specialist at Children's Hospital Boston. "However, newer vaccines are now focused on reducing morbidity, rather than mortality, and we need to carefully weigh the risks and benefits of vaccination. By balancing the costs of a vaccination program and the potential impact of alternative vaccine policies on reducing disease morbidity and improving quality of life, we can optimize decision making regarding vaccine use in the US."
Other study authors included Tracy Lieu, MD, MPH, Center for Child Health Care Studies; Charles LeBaron, MD and Trudy Murphy, MD National Immunization Program, Centers for Disease Control & Prevention; and Susan Lett, MD, MPH, and Stephanie Schauer, PhD, Massachusetts Department of Public Health.
CENTER FOR CHILD HEALTH CARE STUDIES
http://www.hms.harvard.edu/ambulatory/
The Center for Child Health Care Studies is a research center dedicated to improving the health of children. It is located within the Department of Ambulatory Care and Prevention (DACP), a research and teaching collaboration between Harvard Pilgrim Health Care and Harvard Medical School. The principal goals of the DACP are to influence health policy, enhance collaborations between health care delivery systems and traditional public health agencies, train clinicians to manage care effectively, develop improved methods for delivery of health care and develop new information about disease and therapeutics. The DACP conducts research on a wide variety of topics, including cancer, diabetes, asthma, and drug policy. The Center has close ties with Children's Hospital
HARVARD MEDICAL SCHOOL
http://hms.harvard.edu/
Harvard Medical School has more than 5,000 full-time faculty working in eight academic departments based at the School's Boston quadrangle or in one of 47 academic departments at 18 Harvard teaching hospitals and research institutes. Those Harvard hospitals and research institutions include Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Cambridge Health Alliance, The CBR Institute for Biomedical Research, Children's Hospital Boston, Dana-Farber Cancer Institute, Forsyth Institute, Harvard Pilgrim Health Care, Joslin Diabetes Center, Judge Baker Children's Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Massachusetts Mental Health Center, McLean Hospital, Mount Auburn Hospital, Schepens Eye Research Institute, Spaulding Rehabilitation Hospital, VA Boston Healthcare System.